期刊
CEREBROVASCULAR DISEASES
卷 26, 期 3, 页码 317-321出版社
KARGER
DOI: 10.1159/000149580
关键词
cerebrovascular accident; cholinesterase inhibitors; rehabilitation, elderly; cognition, stroke; apathy, stroke
资金
- NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH067710, P30MH071944, K23MH064196] Funding Source: NIH RePORTER
- NIMH NIH HHS [MH067710, K23 MH064196-01, K23 MH064196, MH064196, P30 MH071944, P30 MH071944-01, K23 MH067710] Funding Source: Medline
Background: Impairments in cognition and motivation are common after stroke and predict poor functional recovery. Pharmacological agents that enhance cognition and/or diminish apathy may, when combined with traditional rehabilitative efforts, improve functional recovery. We investigated the feasibility of using acetylcholinesterase inhibitors in older patients with acute post-stroke cognitive impairment and examined their effects on functional recovery. Methods: This 12-week open-label study prospectively treated ischemic stroke survivors aged >= 60 years who were undergoing inpatient rehabilitation and who had cognitive impairment in one or more domains (memory, attention or executive function). Participants received galantamine (maximum dose 24 mg/day) or donepezil (maximum dose 10 mg/day). Physical function was assessed using the Functional Independence Measure-motor subscale (FIM-motor); participants' functional gains were compared to those of a matched historical comparator group. Changes in cognition and apathy were also assessed. Since donepezil and galantamine have different pharmacologic profiles, they were examined separately. Results: Forty participants started study medication; 14 participants terminated prematurely. Donepezil-treated participants experienced a 14-point greater improvement in the FIM-motor score compared to either galantamine-treated participants or the historical comparator group (repeated measures mixed model, group x time interaction p < 0.0001). Change in apathy, but not in cognition, was also associated with change in the FIM-motor score. Conclusions: In this open-label study, participants receiving donepezil had better functional recovery than participants receiving galantamine or the historical comparators. This improvement may reflect efficacy at the starting dose for donepezil but not galantamine. A randomized trial is in progress. Copyright (C) 2008 S. Karger AG, Basel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据